Allopurinol hypersensitivity: A systematic review of all published cases, 1950-2012

Drug Safety

Volumn 36, Issue 10, 2013, Pages 953-980

  Ramasamy, Sheena N ^a,b   Korb Wells, Cameron S ^a,b   Kannangara, Diluk R W ^a,b   Smith, Myles W H ^a,b   Wang, Nan ^a,b   Roberts, Darren M ^a,b   Graham, Garry G ^a,b   Williams, Kenneth M ^a,b   Day, Richard O ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; HLA B ANTIGEN; OXIPURINOL;

AGRANULOCYTOSIS; ANOREXIA; ASIAN; CHEMOPROPHYLAXIS; CHILL; DIARRHEA; DIZZINESS; DRESS SYNDROME; DRUG INDICATION; DRUG SAFETY; EMBASE; EVIDENCE BASED PRACTICE; FEVER; GOUT; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTENSION; HYPOVOLEMIA; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LEUKOPENIA; LYMPHADENOPATHY; MALAISE; MEDLINE; METABOLIC ACIDOSIS; MORTALITY; MYALGIA; NAUSEA; NEOPLASM; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN MANIFESTATION; SORE THROAT; SYSTEMATIC REVIEW; TACHYCARDIA; TACHYPNEA; THROMBOCYTOPENIA;

ALLOPURINOL; DRUG HYPERSENSITIVITY; DRUG UTILIZATION; GOUT; GOUT SUPPRESSANTS; HUMANS;

EID: 84885110998     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0084-0     Document Type: Review

References (463)

1. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64:229-58.
2. Bradlow A. Adverse reactions profile: allopurinol. Prescr J. 1997;37:29-33.
3. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87-114.
4. Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46:623-44.
5. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981;40:245-9.
6. Aubock J, Fritsch P. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. BMJ. 1985;290:1969-70.
7. Lang PG Jr. Severe hypersensitivity reactions to allopurinol. South Med J. 1979;72:1361-8.
8. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82-7.
9. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337-43.
10. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20:391-5.
11. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
12. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135-40.
13. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529-36.
14. Chang HY, Pan WH, Yeh WT, et al. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol. 2001;28:1640-6.
15. Minaur N, Sawyers S, Parker J, et al. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol. 2004;31:965-72.
16. Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther. 2008;10:R17.
17. Anagnostopoulos I, Zinzaras E, Alexiou I, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 2010;11:98.
18. Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;13:R39.
19. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136-41.
20. Robinson PC, Taylor WJ, Merriman TR. Systematic review of the prevalence of gout and hyperuricaemia in Australia. Intern Med J. 2012;42:997-1007.
21. Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51:901-9.
22. Zineh I, Mummaneni P, Lyndly J, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics. 2011;12:1741-9.
23. Chung Y, Lu CY, Graham GG, et al. Utilization of allopurinol in the Australian community. Intern Med J. 2008;38:388-95.
24. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25-32.
25. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.
26. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.
27. Klinenberg JR. The effectiveness of allopurinol in the treatment of gout. Arthritis Rheum. 1965;8:891-5.
28. Scott JT, Hall AP, Grahame R. Allopurinol in treatment of gout. Br Med J. 1966;2:321-7.
29. Blechman WJ, Rosenberg DG, Hilf P. Use of allopurinol in gout, hyperuricemia and uric acid lithiasis. South Med J. 1967;60:215-8.
30. Muggia FM, Ball TJ Jr, Ultmann JE. Allopurinol in the treatment of neoplastic disease complicated by hyperuricemia. Arch Intern Med. 1967;120:12-8.
31. Wilson JD, Simmonds HA, North JD. Allopurinol in the treatment of uraemic patients with gout. Ann Rheum Dis. 1967;26:136-42.
32. Manahan LA, Portes JC. Allopurinol in the treatment of gout. Acta Medica Philipp. 1968;4:189-97.
33. Kantor GL. Toxic epidermal necrolysis, azotemia, and death after allopurinol therapy. JAMA. 1970;212:478-9.
34. Bailey RR, Neale TJ, Lynn KL. Allopurinol-associated arteritis. Lancet. 1976;2:907.
35. Espiritu CR, Alalu J, Glueckauf LG, et al. Allopurinol-induced granulomatous hepatitis. Am J Dig Dis. 1976;21:804-6.
36. Butler RC, Shah SM, Grunow WA, et al. Massive hepatic necrosis in a patient receiving allopurinol. JAMA. 1977;237:473-4.
37. Gelbart DR, Weinstein AB, Fajardo LF. Allopurinol-induced interstitial nephritis. Ann Intern Med. 1977;86:196-8.
38. Medline A, Cohen LB, Tobe BA, et al. Liver granulomas and allopurinol. Br Med J. 1978;1:1320-1.
39. Burkle WS. Allopurinol hypersensitivity. Drug Intell Clin Pharm. 1979;13:218-23.
40. Fam AG, Paton TW, Chaiton A. Reinstitution of allopurinol therapy for gouty arthritis after cutaneous reactions. Can Med Assoc J. 1980;123:128-9.
41. Hamilton DV, Shah PJR, Pryor JS, et al. Acute vasculitis and exacerbation of renal failure secondary to allopurinol hypersensitivity. Dial Transpl. 1980;9:78.
42. Link F, Mueller-Fassbender H. Drug-induced lupus erythematodes (DILE): minor tranquillizers and allopurinol as general inducers of the DILE syndrome? [German] Medikamentos Induzierter Lupus Erythematodes. Minor-Tranquilizers Und Allopurinol Als 'General Inducers' Des Di-Le Syndroms. Munchener Medizinische Wochenschrift. 1980;122:1099-100.
43. Daul AE, Graben N, Anlauf M, et al. Generalized vasculitis as potentially fatal side effect of allopurinol. [German] Generalisierte Vaskulitis Als Lebensbedrohliche Nebenwirkung Von Allopurinol. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin. 1981;87:1235-8.
44. Gotz VP, Salem R. Bullae associated with allopurinol. Drug Intell Clin Pharm. 1981;15:490-1.
45. Lee EJ, Kueh YK. Allopurinol-induced skin reactions and agranulocytosis. Singap Med J. 1982;23:178-80.
46. Ramond MJ, Nouel O, Degott C, et al. Allopurinol-induced hepatitis: report of a case and review of the literature (author's transl). Gastroenterol Clin Biol. 1982;6:138-42.
47. Bruguera M, Libre J, Aubia J, et al. Allopurinol-induced cholestasis. [Spanish] Colestasis Por Alopurinol. Gastroenterologia y Hepatologia. 1983;6:253-5.
48. Halebian P, Corder V, Herndon D, et al. A burn center experience with toxic epidermal necrolysis. J Burn Care Res. 1983;4:176-83.
49. Dan M, Jedwab M, Peled M, et al. Allopurinol-induced toxic epidermal necrolysis. Int J Dermatol. 1984;23:142-4.
50. Fong PH, Ratnagopal P, Wong KL. Drug induced toxic epidermal necrolysis. Singap Med J. 1984;25:184-6.
51. Ebel V, Baumann R, Czechanowski B. Five cases of drug-induced Lyell's syndrome. [German] Funf Falle Mit Medikamenten-Induziertem Lyell-Syndrom. Innere Medizin. 1985;12:280-4.
52. Renwick IG. Asymptomatic hyperuricemia and allopurinol induced toxic epidermal necrolysis. Br Med J. 1985;291:485 (Clinical Research Ed).
53. Zakraoui L, Daly L, Hamza M. Lyell's syndrome happened to a patient treated by allopurinol. [French] Syndrome De Lyell Survenant Chez Une Patiente Traitee Par L'allopurinol. Tunisie Medicale. 1985;63:167-70.
54. Durst UN, Muller E, Pfister T. Toxic epidermal necrolysis (Lyell's syndrome). [German] Toxische Epidermale Nekrolyse (Lyell-Syndrom). Schweiz Med Wochenschr. 1986;116:713-20.
55. Johnston JB, Glazer RI, Pugh L, et al. The treatment of hairy-cell leukaemia with 2′-deoxycoformycin. Br J Haematol. 1986;63:525-34.
56. Kumar L. Allopurinol induced toxic epidermal necrolysis. Indian J Dermatol. 1986;31:53-4.
57. Rayle RT. 5 nursing lessons from a patient with T.E.N. Am J Nurs. 1986;86:300-2.
58. Balacco-Gabrieli C, Palmisano C, Lorusso V, et al. Lyell's syndrome caused by allopurinol. Clinical case. Ophtalmologie. 1988;2:123-6.
59. Sauve C, Pinquier JL, Boissonnad A, et al. Systemic allopurinol toxicity. Eur J Intern Med. 1992;3:78-81.
60. Yu RC, Chu TC. Allopurinol-induced toxic pustuloderma. Br J Dermatol. 1993;128:95-8.
61. Carsuzaa F, Pierre C, Morand JJ, et al. Allopurinol hypersensitivity syndrome: Erythema annulare centrifugum. [French] Syndrome D'hypersensibilite a L'allopurinol a Type D'erytheme Annulaire Centrifuge. Nouvelles Dermatologiques. 1994;13:670-1.
62. Ioannides D, Vakali G, Chrysomallis F, et al. Toxic epidermal necrolysis: a study of 22 cases. J Eur Acad Dermatol Venereol. 1994;3:266-75.
63. Richter G, Blasum C. Allopurinol hypersensitivity syndrome. [German] Allopurinol-Hypersensitivitatssyndrom. Aktuelle Dermatologie. 1994;20:217-9.
64. Bang HD, Chung JH, Cho KH, et al. Three cases of allopurinol hypersensitivity syndrome. Korean J Dermatol. 1995;33:130-4.
65. Baroni T, Bocor M. Erythemato-maculo-papular eruption induced by allopurinol. [Italian] Eruzione Eritemato-Maculo-Papulosa Da Allopurinolo. Giornale Italiano di Dermatologia e Venereologia. 1995;130:45-7.
66. Domingues-Costa A, Marques P, Vaz-Da-Silva M. The allopurinol hypersensitivity syndrome: A case report. [Portuguese] Sindrome De Hipersensibilidade Ao Alopurinol. A Proposito De Um Caso Clinico. Arquivos de Medicina. 1996;10:48-54.
67. Kruppa A, Smola H, Scharffetter-Kochanek K, et al. Allopurinol-induced allergic vasculitis. [German] Vasculitis allergica auf Allopurinol. H+G Zeitschrift fur Hautkrankheiten. 1996;71:868-9.
68. Gimbel Moral LF, De Miguel Sanchez C, Mugarza Hernandez MD, et al. Erupcion Fija Medicamentosa Causada Por Alopurinol. Medicina Clinica. 1996;106:119.
69. Sabaris Ma CF, Duran EP, Garcia-Patos PE, et al. Generalized acute exanthematic pustulosis due to allopurinol. [Spanish] Pustulosis exantematica aguda generalizada por alopurinol. Actas Dermo-Sifiliograficas. 1996;87:471-4.
70. Akriditis NK, Sakkas LI. Leukocytoclastic vasculitis. Consultant. 1997;37:1414.
71. Higuchi S, Yamamoto M. A case of Stevens-Johnson syndrome associated with allopurinol hypersensitivity [Japanese]. Acta Dermatologica Kyoto. 1997;92:367-73.
72. Schnyder B, Zanni MP, Pichler WJ. Drug-induced hypersensitivity syndrome. A review and presentation of 2 personal cases. Schweiz Med Wochenschr. 1997;127:355-9.
73. Calvino JA, Burgos RR, Mardaras J, et al. Hypersensitivity syndrome and granulomatous interstitial nephritis associated with allopurinol. [Spanish] Sindrome de hipersensibilidad y nefritis intersticial granulomatosa aguda asociada al alopurinol. Nefrologia. 1998;18:238-42.
74. Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139:1026-32.
75. Kluger E. Fatal outcome in allopurinol hypersensitivity syndrome. Ugeskr Laeger. 1998;160:1179-80.
76. Torralba FJ, Sanchez-Carbayo M, Gil MT, et al. Allopurinol hypersensitivity. [Spanish] Hipersensibilidad a alopurinol. Nefrologia. 1998;18:81-5.
77. Voets AJ, Joesoef KS. Allopurinol toxicity after coronary artery bypass grafting. Clin Intensive Care. 1998;9:88-9.
78. Wooten MD, Lipsmeyer E. Gout accompanying rheumatoid arthritis: a comparison of affected women and men. J Clin Rheumatol. 1998;4:220-4.
79. Hari Y, Urwyler A, Hurni M, et al. Distinct serum cytokine levels in drug- and measles-induced exanthema. Int Arch Allergy Immunol. 1999;120:225-9.
80. Buna D. Allopurinol hypersensitivity syndrome: a case report and review. Can J Hosp Pharm. 2000;53:36-9.
81. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981-3.
82. Hari Y, Frutig-Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy. 2001;31:1398-408.
83. Ortega JD, Trindade C, Llamazares A, et al. Hypersensitivity to allopurinol. Efficacy of a desensitization procedure in three cases. [Spanish] Hipersensibilidad al alopurinol. Eficacia de un protocolo de desensibilizacion en tres casos. Anales de Medicina Interna. 2001;18:27-8.
84. Hoffman LA. My gout and allopurinol desensitization. J Clin Rheumatol. 2002;8:354-7.
85. Joshi A, Verma A, Gulati A, et al. Toxic epidermal necrolysis in a patient of chronic myeloid leukemia treated successfully with high dose steroids. J Inter Med India. 2002;5:40-2.
86. Maejima H, Mukai H, Hikaru E. Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide. Acta Derm Venereol. 2002;82:316-7.
87. Nishimura S, Shinoda T, Suzuki Y, et al. Drug-induced MPO-ANCA-positive necrotizing crescentic glomerulonephritis preceded by granulomatous hepatitis. Clin Exp Nephrol. 2002;6:118-20.
88. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109:155-61.
89. Sommers LM, Schoene RB. Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities and new-onset diabetes mellitus. Arch Intern Med. 2002;162:1190-2.
90. Chubar Y, Bennett M. Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol. Br J Haematol. 2003;122:768-70.
91. Hirashima N, Misago N, Nakafusa J, et al. Two cases of drug-induced hypersensitivity syndrome [Japanese]. Nishinihon J Dermatol. 2003;65:365-9.
92. Kim BJ, Kim MN, Ro BI, et al. A case of allopurinol hypersensitivity syndrome [Korean]. Korean J Dermatol. 2003;41:251-4.
93. Nitti F, Fumagalli M, Incorvaia C. Rush desensitization to allopurynol. Allergy. 2003;58:690.
94. Koizumi H, Tsunoda T, Ito O, et al. A case of drug-induced hypersensitivity syndrome (DIHS) caused by allopurinol [Japanese]. Nishinihon J Dermatol. 2004;66:37-9.
95. Takayasu S, Nasu N, Hoshino T, et al. Drug eruption associated with allopurinol and vancomycin in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). A case report [Japanese]. Nishinihon J Dermatol. 2004;66:479-81.
96. Cho WI, Yoon YH, Kim MN, et al. Two cases of allopurinol hypersensitivity syndrome due to use of allopurinol for the patient with asymptomatic hyperuricemia [Korean]. Korean J Dermatol. 2005;43:961-4.
97. Kim JW, Kim JS, Kim KJ. A clinical observation of drug hypersensitivity syndrome and serologic and molecular genetic analyses of human herpesvirus-6 reactivation [Korean]. Korean J Dermatol. 2005;43:143-50.
98. Kwon KS, Kim BS, Jang BS, et al. Clinical study of drug rash with eosinophilia and systemic symptoms (DRESS) on drug eruption patients over the last 10 years (1995-2004) [Korean]. Korean J Dermatol. 2005;43:1164-9.
99. Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J. 2005;35:188-90.
100. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504-10.
101. Mantha S, Jacobs MI, Savage DG. Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia. J Clin Oncol. 2005;23:5841-3.
102. Marie E, Fournier C, Bautin N, et al. Ultra-rush desensitization to allopurinol. [French] Accoutumance ultrarapide a l'allopurinol. Revue Francaise d'Allergologie et d'Immunologie Clinique. 2005;45:498-500.
103. Park MW, Kim SS, Lee JJ. Two cases of allopurinol hypersensitivity syndrome [Korean]. Korean J Dermatol. 2005;43:114-7.
104. Song HJ, Kim CO, Lee KS. Two cases of allopurinol hypersensitivity syndrome in patients receiving thiazide therapy due to hypertension [Korean]. Korean J Dermatol. 2005;43:1426-9.
105. Stingeni L, Zeppa L, Lisi P. Allopurinol induced DRESS syndrome: Clinical and pathogenetic remarks. [Italian] Sindrome da ipersensibilita ad allopurinolo: Considerazioni clinicopatogenetiche. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale. 2005;59:115-7.
106. Wang D, Xhu XJ. Gouty patient hypersensitive to allopurinol: an intractable case. J Dermatol. 2005;32:64-5.
107. Das R. Allopurinol-associated angitis. J Pharm Pract Res. 2006;36:77.
108. Seishima M, Yamanaka S, Fujisawa T, et al. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006;155:344-9.
109. Torres MJ, Mayorga C, Fernandez TD, et al. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int J Immunopathol Pharmacol. 2006;19:119-30.
110. Vahid B, Wildemore B, Lin T, et al. What caused diffuse alveolar hemorrhage in a patient with gout? J Respir Dis. 2006;27:441-3.
111. Wung DC, Cheng MF, Huang JJ, et al. Corticosteroid therapy in allopurinol hypersensitivity syndrome: a case report [Chinese]. J Intern Med Taiwan. 2006;17:133-40.
112. Calogiuri G, Muratore L, Congedo M, et al. Alternative treatments in allopurinol hypersensitivity syndrome: a case report. [Italian] Alternative terapeutiche nella sindrome da ipersensibilita all'allopurinolo: Descrizione di un caso clinico. Italian. J Allergy Clin Immunol. 2007;17:66-70.
113. Cornejo-Garcia JA, Fernandez TD, Torres MJ, et al. Differential cytokine and transcription factor expression in patients with allergic reactions to drugs. Allergy. 2007;62:1429-38.
114. Gravante G, Delogu D, Marianetti M, et al. Toxic epidermal necrolysis and Steven-Johnson syndrome: 11-years experience and outcome. Eur Rev Med Pharmacol Sci. 2007;11:119-27.
115. Nishio D, Izu K, Kabashima K, et al. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci. 2007;48:25-33.
116. Paquet P, Jacob E, Quatresooz P, et al. Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis. Burns. 2007;33:100-4.
117. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56:419-25.
118. Fortunati M, Dewulf V, Jouret F, et al. "DRESS syndrome"or systemic allopurinol hypersensitivity syndrome. [French] «DRESS syndrome» ou syndrome d'hypersensibilite systemique a l'allopurinol. Louvain Med. 2008;127:376-9.
119. Roche Gamon E, Carazo JLS, Argente CL, et al. Delayed allopurinol hypersensitivity syndrome. [Spanish] Sindrome de hipersensibilidad retardada a alopurinol. Piel. 2008;23:166-8.
120. Koike M, Kanno Y, Tomori K, et al. Viruses may trigger allopurinol hypersensitivity syndrome. NDT Plus. 2008;1:273-4.
121. Tausche AK, Aringer M, Schroeder HE, et al. The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med. 2008;121:e3-4.
122. Tohyama M, Shirakata Y, Sayama K, et al. A marked increase in serum soluble Fas ligand in drug-induced hypersensitivity syndrome. Br J Dermatol. 2008;159:981-4.
123. Asano Y, Kagawa H, Kano Y, et al. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol. 2009;145:1030-6.
124. Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum. 2009;61:1268-70.
125. Kemen C, Lemke J, Hoeger PH, et al. Human leukocyte antigen-related risk factors for toxic epidermal necrosis. Pediatr Infect Dis J. 2009;28:552.
126. Tamzaourte M, Errabih I, Krami H, et al. Acute cytolytic hepatitis induced by allopurinol in a patient treated for hepatitis C. [French] Hepatite aigue cytolytique induite par l'allopurinol chez un patient traite pour hepatite virale C. Journal Africain d'Hepato-Gastroenterologie. 2009;3:160-2.
127. Ang CC, Wang YS, Yoosuff EL, et al. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol. 2010;63:219-27.
128. Bellon T, Alvarez L, Mayorga C, et al. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases. Br J Dermatol. 2010;162:1014-22.
129. Bennett S, Mitsides N, Dhaygude A, et al. A pilot in distress. NDT Plus. 2010;3:84-8.
130. Chaabane A, Aouam K, Fredj NB, et al. DRESS syndrome: 11 Case reports and a literature review. [French] DRESS syndrome: Etude de 11 cas et revue de la litterature. Therapie. 2010;65:543-50.
131. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146:1373-9.
132. Cooksley T, Iqbal J, Robertson C, et al. DRESS syndrome caused by allopurinol. Acute Med. 2010;9:122-3.
133. Elia F, Apra F. A potentially fatal cause of rash. Int J Emerg Med. 2010;3:491-2.
134. Flores SM, Hidalgo LG, Topete RO. Erithrodermia as presentation of DRESS syndrome associated with allopurinol. A report of a case. [Spanish] Eritrodermia como presentacion del sindrome DRESS asociado con alopurinol. Comunicacion de un caso. Dermatologia Revista Mexicana. 2010;54:104-7.
135. Ben Fredj N, Aouam K, Chaabane A, et al. Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. Br J Clin Pharmacol. 2010;70:273-6.
136. Lee T, Bae YJ, Park SK, et al. Severe pneumonia caused by combined infection with Pneumocystis jiroveci, parainfluenza virus type 3, cytomegalovirus, and Aspergillus fumigatus in a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2010;90:625-9.
137. Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, et al. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on human herpesvirus 6 replication in vitro. Eur J Dermatol. 2010;20:68-73.
138. Peppercorn AF, Miller MB, Fitzgerald D, et al. High-level human herpesvirus-6 viremia associated with onset of Stevens-Johnson syndrome: report of two cases. J Burn Care Res. 2010;31:365-8.
139. Cardoso CS, Vieira AM, Oliveira AP. DRESS syndrome: a case report and literature review. BMJ Case Rep. 2011. doi: 10.1136/bcr.02.2011.3898.
140. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38:1957-9.
141. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transpl. 2011;26:3567-72.
142. Natkunarajah J, Goolamali S, Craythorne E, et al. Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone. Eur J Dermatol. 2011;21:385-91.
143. Ranu H, Jiang J, Ming PS. A case series of allopurinol-induced toxic epidermal necrolysis. Indian J Dermatol. 2011;56:74-6.
144. Teo WL, Pang SM, Koh HY. Allopurinol hypersensitivity syndrome with acute generalized exanthematous pustulosis manifestations. Cutan Ocul Toxicol. 2011;30:243-4.
145. Aach R, Kissane J. Hypertension, hyperuricemia and iatrogenic disease. Am J Med. 1970;49:242-9.
146. Jarzobski J, Ferry J, Wombolt D, et al. Vasculitis with allopurinol therapy. Am Heart J. 1970;79:116-21.
147. Mills RM Jr. Severe hypersensitivity reactions associated with allopurinol. JAMA. 1971;216:799-802.
148. Simmons F, Feldman B, Gerety D. Granulomatous hepatitis in a patient receiving allopurinol. Gastroenterology. 1972;62:101-4.
149. Young JL Jr, Boswell RB, Nies AS. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med. 1974;134:553-8.
150. Ellman MH, Fretzin DF, Olson W. Toxic epidermal necrolysis associated with allopurinol administration. Arch Dermatol. 1975;111:986-90.
151. Boyer TD, Sun N, Reynolds TB. Allopurinol-hypersensitivity vasculitis and liver damage. West J Med. 1977;126:143-7.
152. Lockard O Jr, Harmon C, Nolph K, et al. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med. 1976;85:333-5.
153. McMenamin RA, Davies LM, Craswell PW. Drug induced interstitial nephritis, hepatitis and exfoliative dermatitis. Aust N Z J Med. 1976;6:583-7.
154. Utsinger PD, Young WJ. Allopurinol hypersensitivity. Granular deposition of IgM at the dermal-epidermal junction. Am J Med. 1976;61:287-94.
155. Chan HL, Ku G, Khoo OT. Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. Aust N Z J Med. 1977;7:518-22.
156. Devulder B, Plouvier B, Francois M, et al. Zeek's angiitis during combination treatment with allopurinol and a thiazide diuretic. Lille Med. 1977;22:798-800.
157. Calin A. Allopurinol toxicity masquerading as malignancy. JAMA. 1978;239:497.
158. Korting HC, Lesch R. Acute cholangitis after allopurinol treatment. Lancet. 1978;1:275-6.
159. Lindsey SW, Evans EF. Allpurinol hypersensitivity syndrome: effects and treatment. Va Med. 1978;105:297-9.
160. Male PJ, Schaer B, Posternak F. Hypersensitivity reaction to allopurinol. Schweiz Med Wochenschr. 1978;108:681-3.
161. Swank LA, Chejfec G, Nemchausky BA. Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch Intern Med. 1978;138:997-8.
162. Haughey DB, Lanse S, Imhoff T, et al. Allopurinol sensitivity: report of two cases. Am J Hosp Pharm. 1979;36:1377-80.
163. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979;1:365-74.
164. McKendrick MW, Geddes AM. Allopurinol hypersensitivity. Br Med J. 1979;1:988.
165. Phanichphant S, Boonpucknavig V. Allopurinol associated hypersensitivity. J Med Assoc Thai. 1980;63:155-63.
166. Al-Kawas FH, Seeff LB, Berendson RA, et al. Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med. 1981;95:588-90.
167. Grussendorf M, Andrassy K, Waldherr R, et al. Systemic hypersensitivity to allopurinol with acute interstitial nephritis. Am J Nephrol. 1981;1:105-9.
168. Irino S, Sanada H, Maesako N, et al. A case of angio-immunoblastic lymphadenopathy with dysproteinemia related to allopurinol. Acta Med Okayama. 1981;35:263-72.
169. Earll JM, Saavedra M. Oxipurinol therapy in allopurinol-allergic patients. Am Fam Physician. 1983;28:147-8.
170. Ohsawa T, Ohtsubo M. Hepatitis associated with allopurinol. Drug Intell Clin Pharm. 1985;19:431-3.
171. Stein CM. Allopurinol hypersensitivity. A case report. S Afr Med J. 1985;67:935-6.
172. Webster E, Panush RS. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout. Arthritis Rheum. 1985;28:707-9.
173. Guerin C, Genin C, Toulon J, et al. Allopurinol toxicity. Apropos of 1 case. Nephrologie. 1986;7:47-9.
174. Handa SP. Drug-induced acute interstitial nephritis: report of 10 cases. CMAJ. 1986;135:1278-81.
175. Magner P, Sweet J, Bear RA. Granulomatous interstitial nephritis associated with allopurinol therapy. CMAJ. 1986;135:496-7.
176. Mousson C, Justrabo E, Tanter Y, et al. Acute granulomatous interstitial nephritis and hepatitis caused by drugs. Possible role of an allopurinol-furosemide combination. Nephrologie. 1986;7:199-203.
177. Pan HY, Glazener FS. The mackerel was in fact a red herring. Drug Intell Clin Pharm. 1986;20:687-9.
178. Schillinger F, Montagnac R, Milcent T. A new case of severe allopurinol toxicity. Nephrologie. 1986;7:214.
179. Vanderstigel M, Zafrani ES, Lejonc JL, et al. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin-ring granulomas. Gastroenterology. 1986;90:188-90.
180. Arbeteta J, Ledo L, Teruel JL, et al. Severe adverse reaction to allopurinol. Med Clin (Barc). 1987;88:125-6.
181. Pewsner D, Bachmann C, Muller U. Allopurinol-induced kidney failure with hepatitis and squamous dermatitis in pre-existing kidney insufficiency. Schweiz Med Wochenschr. 1987;117:139-41.
182. Emmerson BT, Hazelton RA, Frazer IH. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum. 1988;31:436-40.
183. Foucault V, Pibouin M, Lehry D, et al. Severe drug accidents and allopurinol. Ann Dermatol Venereol. 1988;115:1169-72.
184. McDonald J, Fam AG, Paton T, et al. Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. J Rheumatol. 1988;15:865-8.
185. Casas E, Puig JG, Mateos FA, et al. The allopurinol hypersensitivity syndrome: its relation to plasma oxypurinol levels. Adv Exp Med Biol. 1989;253A:257-60.
186. Coutellier P, Delgrange B. Fatal toxic epidermolysis following administration of allopurinol. Acta Clin Belg. 1989;44:196-8.
187. Gram JT, Gundersen T. Allopurinol hypersensitivity syndrome. Tidsskr Nor Laegeforen. 1989;109:3102-4.
188. Puig JG, Casas EA, Ramos TH, et al. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J Rheumatol. 1989;16:842-4.
189. Stricker BH, Blok AP, Babany G, et al. Fibrin ring granulomas and allopurinol. Gastroenterology. 1989;96:1199-203.
190. Chong RS, Ng HS, Teh LB, et al. Hepatic granulomas: an experience over the last 8 years. Singap Med J. 1990;31:422-6.
191. Collins CE, Thomas DJ, Gumpel JM. Catatonia in the allopurinol hypersensitivity syndrome. BMJ. 1991;302:970.
192. Marazuela M, Moreno A, Yebra M, et al. Hepatic fibrin-ring granulomas: a clinicopathologic study of 23 patients. Hum Pathol. 1991;22:607-13.
193. Walz-LeBlanc BA, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum. 1991;34:1329-31.
194. Fam AG, Lewtas J, Stein J, et al. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med. 1992;93:299-302.
195. San Andres Rebollo FJ, Gonzalez Rubio M, Postigo C, et al. Hypersensitivity syndrome caused by allopurinol: report of 2 cases and review of the literature. Rev Clin Esp. 1992;191:426-9.
196. Huang RY, Liu HN, Wong CK. Stevens-Johnson syndrome: a review of 42 cases. Zhonghua Yi Xue Za Zhi (Taipei). 1993;51:225-30.
197. Berbegal J, Morera J, Andrada E, et al. Syndrome of allopurinol hypersensitivity. Report of a new case and review of the Spanish literature. Med Clin (Barc). 1994;102:178-80.
198. Braden GL, Warzynski MJ, Golightly M, et al. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol. 1994;70:145-51.
199. Fitzgerald DA, Heagerty AH, Stephens M, et al. Follicular toxic pustuloderma associated with allopurinol. Clin Exp Dermatol. 1994;19:243-5.
200. Hanger HC, Pillans PI. Death following allopurinol hypersensitivity syndrome. N Z Med J. 1994;107:229.
201. Lee SS, Lin HY, Wang SR, et al. Allopurinol hypersensitivity syndrome. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1994;27:140-7.
202. Salinas Martin A, Mendez Abad M, Miguelez M, et al. Hypersensitivity reaction to allopurinol. Aten Primaria. 1994;14:694.
203. Elasy T, Kaminsky D, Tracy M, et al. Allopurinol hypersensitivity syndrome revisited. West J Med. 1995;162:360-1.
204. Gonzalez U, Reyes E, Kershenovich J, et al. Hypersensitivity syndrome caused by allopurinol. A case of massive hepatic necrosis. Rev Invest Clin. 1995;47:409-13.
205. Parra E, Gota R, Gamen A, et al. Granulomatous interstitial nephritis secondary to allopurinol treatment. Clin Nephrol. 1995;43:350.
206. Urban T, Maquarre E, Housset C, et al. Allopurinol hypersensitivity: a possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment. Rev Mal Respir. 1995;12:314-6.
207. Kumar A, Edward N, White MI, et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ. 1996;312:173-4.
208. Rothwell PM, Grant R. Cerebral vasculitis following allopurinol treatment. Postgrad Med J. 1996;72:119-20.
209. Andrade RJ, de la Mata M, Lucena MI, et al. Severe acute hepatitis due to allopurinol in a patient with asymptomatic hyperuricemia and kidney failure. A review of the literature and an analysis of the risk factors. Gastroenterol Hepatol. 1997;20:353-6.
210. Carpenter C. Allopurinol hypersensitivity syndrome. Tenn Med. 1997;90:151-2.
211. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23:1237-44.
212. Choi HK, Merkel PA, Niles JL. ANCA-positive vasculitis associated with allopurinol therapy. Clin Exp Rheumatol. 1998;16:743-4.
213. Gillott TJ, Whallett A, Zaphiropoulos G. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity. Rheumatology (Oxford). 1999;38:85-6.
214. Grahame R, Simmonds HA, McBride MB, et al. How should we treat tophaceous gout in patients with allopurinol hypersensitivity? Adv Exp Med Biol. 1998;431:19-23.
215. Hamanaka H, Mizutani H, Nouchi N, et al. Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol. Clin Exp Dermatol. 1998;23:32-4.
216. Jappe U, Franke I, Wendekamm U, et al. Allopurinol as an inducer of acute graft-versus-host-like drug reaction. Case report with review of the literature. Hautarzt. 1998;49:126-30.
217. Pereira S, Almeida J, Silva AO, et al. Fatal liver necrosis due to allopurinol. Acta Med Port. 1998;11:1141-4.
218. Pluim HJ, van Deuren M, Wetzels JF. The allopurinol hypersensitivity syndrome. Neth J Med. 1998;52:107-10.
219. Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol. 1998;134:1108-12.
220. Woss E, Neyer U. Hypersensitivity angiitis following allopurinol therapy. Fortschr Med. 1988;106(730-1):29.
221. Morel D, Guez S, Merville P, et al. Recurrent renal failure associated with hypersensitivity to allopurinol. Nephrol Dial Transpl. 1999;14:780-1.
222. Tanna SB, Barnes JF, Seth SK. Desensitization to allopurinol in a patient with previous failed desensitization. Ann Pharmacother. 1999;33:1180-3.
223. Aoki S, Kotooka N, Yokoyama M, et al. Recurrence of rapidly progressive glomerulonephritis probably associated with two different kinds of drugs. Clin Nephrol. 2000;54:249-51.
224. Brand R, Rohr JB. Toxic epidermal necrolysis in Western Australia. Australas J Dermatol. 2000;41:31-3.
225. Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singap Med J. 2000;41:156-60.
226. Arakawa M, Kakuto Y, Ichikawa K, et al. Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia. Intern Med. 2001;40:331-5.
227. Benito-Leon J, Porta-Etessam J. Guillain-Barre syndrome and allopurinol-induced hypersensitivity. Eur Neurol. 2001;45:186-7.
228. Hammer B, Link A, Wagner A, et al. Hypersensitivity syndrome during therapy with allopurinol in asymptomatic hyperuricemia with a fatal outcome. Dtsch Med Wochenschr. 2001;126:1331-4.
229. Rivas Gonzalez P, Calvo Hernandez R, Molinelli Barranco M, et al. Allopurinol hypersensitivity syndrome. Rev Clin Esp. 2001;201:493.
230. Anderson BE, Adams DR. Allopurinol hypersensitivity syndrome. J Drugs Dermatol. 2002;1:60-2.
231. Descamps V, Mahe E, Houhou N, et al. Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection. Br J Dermatol. 2003;148:1032-4.
232. Fine P, Savrinski B, Millodot M. Contact lens management of a case of Stevens-Johnson syndrome: a case report. Optometry. 2003;74:659-64.
233. Masaki T, Fukunaga A, Tohyama M, et al. Human herpes virus 6 encephalitis in allopurinol-induced hypersensitivity syndrome. Acta Derm Venereol. 2003;83:128-31.
234. Mete N, Yilmaz F, Gulbahar O, et al. Allopurinol hypersensitivity syndrome as a cause of hepatic centrilobular hemorrhagic necrosis. J Investig Allergol Clin Immunol. 2003;13:281-3.
235. Dia D, Ba-Fall K, Bouldouyre M, et al. DRESS syndrome to allopurinol: a case in Dakar. Dakar Med. 2004;49:114-5.
236. Marrakchi C, Kanoun F, Kilani B, et al. Allopurinol induced DRESS syndrome. Rev Med Interne. 2004;25:252-4.
237. Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease. Ann Pharmacother. 2005;39:1552-6.
238. Chen IH, Kuo MC, Hwang SJ, et al. Allopurinol-induced severe hypersensitivity with acute renal failure. Kaohsiung J Med Sci. 2005;21:228-32.
239. Choi SH, Yang SH, Song YB, et al. A case of vanishing bile duct syndrome associated with hypersensitivity to allopurinol. Korean J Hepatol. 2005;11:80-5.
240. Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ. 2005;331:623-4.
241. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134-9.
242. Kakeda M, Tohyama M, Iwasaki J, et al. A case of histopathologically typical toxic epidermal necrolysis despite no visible blisters or erosive lesions. J Dermatol. 2005;32:654-60.
243. Saxena R, Loghmanee F. Fatal drug reaction due to allopurinol therapy in a 72-year-old man. Arch Pathol Lab Med. 2005;129:e183-4.
244. Almirall J, Orellana R, Martinez Ocana JC, et al. Allopurinol-induced chronic granulomatous interstitial nephritis. Nefrologia. 2006;26:741-4.
245. Kokunai A, Azusawa H, Murota H, et al. Hypersensitivity reactions to multiple drugs during the course of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Arerugi. 2006;55:662-6.
246. Rodevand E, Sletvold O, Kvande KT. Side effects off allopurinol. Tidsskr Nor Laegeforen. 2004;124:2618-9.
247. Dainichi T, Uchi H, Moroi Y, et al. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology. 2007;215:86-8.
248. Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007;157:934-40.
249. Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22:1044-9.
250. Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008;70:523-6.
251. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singap Med J. 2008;49:384-7.
252. Shalom R, Rimbroth S, Rozenman D, et al. Allopurinol-induced recurrent DRESS syndrome: pathophysiology and treatment. Ren Fail. 2008;30:327-9.
253. Suzuki HI, Asai T, Tamaki Z, et al. Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia. Haematologica. 2008;93:469-70.
254. Yoon JY, Min SY, Park JY, et al. A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. Korean J Hepatol. 2008;14:97-101.
255. Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145:67-72.
256. Gyotoku E, Iwamoto T, Ochi M. A fatal case of drug-induced hypersensitivity syndrome due to allopurinol. Arerugi. 2009;58:560-6.
257. Hung CC, Liu WC, Kuo MC, et al. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29:633-8.
258. Hsieh HJ, Chan AL, Lin SJ. Stevens-Johnson syndrome induced by combination of imatinib and allopurinol. Chemotherapy. 2009;55:197-9.
259. Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68:51-6.
260. Sackesen C, Dut R, Gucer S, et al. Allopurinol-induced DRESS syndrome in a 13-year-old girl. J Investig Allergol Clin Immunol. 2009;19:65-7.
261. Dewan AK, Quinonez RA. Allopurinol-induced DRESS syndrome in an adolescent patient. Pediatr Dermatol. 2010;27:270-3.
262. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2010;49:834-41.
263. Fathallah N, Ben Salem C, Slim R, et al. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities. J Clin Rheumatol. 2010;16:170-1.
264. Hamaguchi Y, Fujimoto M, Enokido Y, et al. Intractable genital ulcers from herpes simplex virus reactivation in drug-induced hypersensitivity syndrome caused by allopurinol. Int J Dermatol. 2010;49:700-4.
265. Santiago F, Goncalo M, Vieira R, et al. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermat. 2010;62:47-53.
266. Ventura F, Fracasso T, Leoncini A, et al. Death caused by toxic epidermal necrolysis (Lyell syndrome). J Forensic Sci. 2010;55:839-41.
267. Yang DC, Chang CM. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome with recurrence. J Am Geriatr Soc. 2010;58:2043-4.
268. Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med. 2012;125:1126 e7-34 e7.
269. Sekine A, Saito T, Ito S, et al. Two cases of tuberculosis with multiple drug hypersensitivity after drug-induced hypersensitivity syndrome. Respir Investig. 2012;50:70-5.
270. Agnes K, Anna L, Anita V, et al. Allopurinol-induced hypersensitivity syndrome. Orvosi Hetilap. 2012;153:586-91.
271. Cao ZH, Wei ZY, Zhu QY, et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics. 2012;13:1193-201.
272. Comparin C, Hans Filho G, Takita LC, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases. An Bras Dermatol. 2012;87:477-81.
273. Kamal T, Elnikety S, Mashaly H, et al. Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report. J Med Case Rep. 2012;6:84.
274. Biagioni E, Busani S, Rinaldi L, et al. Acute renal failure and liver necrosis associated to allopurinol therapy. Anaesth Intensive Care. 2012;40:190-1.
275. Botelho LF, Higashi VS, Padilha MH, et al. DRESS: clinicopathological features of 10 cases from an University Hospital in Sao Paulo. An Bras Dermatol. 2012;87:703-7.
276. Chiu ML, Hu M, Ng MH, et al. Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol. 2012;167:44-9.
277. Gordon K, Miteva M, Torchia D, et al. Allopurinol-induced palisaded neutrophilic and granulomatous dermatitis. Cutan Ocul Toxicol. 2012;31:338-40.
278. Huang YC, Shih PY, Chin SY, et al. Allopurinol-induced drug rash with eosinophilia and systemic symptoms mimicking acute generalized exanthematous pustulosis. J Dermatol. 2012;39:1077-8.
279. Lee MH, Stocker SL, Anderson J, et al. Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? Intern Med J. 2012;42:411-6.
280. Martinez-Aranguren R, Gamboa PM, Garcia-Lirio E, et al. In vitro cytokine production after in vivo desensitization in an allopurinol-induced delayed allergic reaction. Ann Allergy Asthma Immunol. 2012;108:280-1.
281. Yaylaci S, Demir MV, Temiz T, et al. Allopurinol-induced DRESS syndrome. Indian J Pharmacol. 2012;44:412-4.
282. Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P, et al. Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms. Acta Derm Venereol. 2012;92:200-5.
283. Onuma H, Tohyama M, Imagawa A, et al. High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome. J Clin Endocrinol Metab. 2012;97:E2277-81.
284. Laguna C, Martin B, Torrijos A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. Actas Dermo-Sifiliograficas. 2006;97:177-85.
285. Raymond JZ, Goldman HM. An unusual cutaneous reaction secondary to allopurinol. Cutis. 1988;41:323-6.
286. Fonseka MM, Sathischandra H, Jayamanne SF, et al. Successful desensitisation of allopurinol-induced erythema multiforme. Ceylon Med J. 1999;44:190-1.
287. Edwards R, Ridder M. Stevens-Johnson syndrome: a multisystem case. Dimens Crit Care Nurs. 1985;4:335-48.
288. Teo L, Tay YK, Liu TT, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. Singap Med J. 2009;50:29-33.
289. Turki H, Walha N, Boudaya S, et al. Le syndrome de Lyell (nécrolyse épidermique toxique). Étude de 8 cas. Sem Hôp Paris. 1998;74:953-8.
290. Gil Gonzalez I, Gimenez Garcia RM, Diez Gonzalez G, et al. Toxic epidermal necrolysis caused by allopurinol. Anales de Medicina Interna. 1988;5:649.
291. Quintas S, Do Carmo G, Gama R, et al. Lyell's syndrome in a patient with AIDS. Acta Medica Portuguesa. 1997;10:509-16.
292. Cid Conde L, Novoa Fernandez E, Padron Rodriguez B. Toxic epidermal necrolysis (Lyell's syndrome) secondary to alopurinol. Farmacia Hospitalaria. 2009;33:229-30.
293. Knezevic A, Frkovic A, Francetic I, et al. Toxic epidermal necrolysis (Lyell's syndrome) caused by allopurinol. Lijecnicki Vjesnik. 1987;109:272-4.
294. Dicle Ö, Yilmaz E, Alpsoy E. Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective evaluation. Türkderm Deri Hastaliklari ve Frengi Arsivi. 2009;43:15-20.
295. Assaad D, From L, Ricciatti D, et al. Toxic epidermal necrolysis in Stevens-Johnson syndrome. Can Med Assoc J. 1978;118:154-6.
296. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol. 1994;130:605-8.
297. Gambert SR. Medication-induced Stevens-Johnson syndrome in elders. Clin Geriatr. 2012;20:8.
298. Stenton SB, Dalen D, Wilbur K. Myocardial infarction associated with intravenous immune globulin. Ann Pharmacother. 2005;39:2114-8.
299. Bennett TO, Sugar J, Sahgal S. Ocular manifestations of toxic epidermal necrolysis associated with allopurinol use. Arch Ophthalmol. 1977;95:1362-4.
300. Cheriyan S, Patterson R, Greenberger PA, et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc. 1995;16:151-5.
301. Chaidemenos GC, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218-21.
302. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;92:62-6.
303. Patterson R, Cheriyan S, Greenberger PA. Recurrent dermopathy after remission of Stevens-Johnson syndrome secondary to mild dermal trauma. Allergy Proc. 1995;16:115-8.
304. Struck MF, Illert T, Schmidt T, et al. Secondary abdominal compartment syndrome in patients with toxic epidermal necrolysis. Burns. 2012;38:562-7.
305. Yun SJ, Choi MS, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology. 2008;217:254-9.
306. Trautmann A, Klein CE, Kampgen E, et al. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol. 1998;139:1127-8.
307. Arevalo JM, Lorente JA. Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil. 1999;20:406-10.
308. Moniz P, Casal D, Mavioso C, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 15-year retrospective study. Acta Med Port. 2011;24:59-70.
309. Ziemer M, Kardaun SH, Liss Y, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166:575-600.
310. Davies P, Ryan DW. Stevens-Johnson syndrome managed in the Clinitron bed. Intensive Care Med. 1983;9:87-9.
311. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704-9.
312. Kelso JM, Keating RM. Successful desensitization for treatment of a fixed drug eruption to allopurinol. J Allergy Clin Immunol. 1996;97:1171-2.
313. Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology. 2004;209:29-32.
314. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol. 2005;30:600-2.
315. Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns. 2001;27:372-5.
316. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26-32.
317. Fania L, Giannico MI, Fasciani R, et al. Ocular mucous membrane pemphigoid after Lyell syndrome: occasional finding or predisposing event? Ophthalmology. 2012;119:688-93.
318. Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs. 1991;14:634-8.
319. Marra LM, Wunderle RC. Oral presentation of toxic epidermal necrolysis. J Oral Maxillofac Surg. 1982;40:59-61.
320. Carmona AF, Redondo AD, Pena LO, et al. Toxic epidermal necrolysis treated with cyclosporin A. Med Intensiva. 2011;35:442-5.
321. Bashir S, Shah SM, Babar I. Allopurinol induced Stevens-Johnson syndrome: a case report. J Pak Med Assoc. 2000;50:207-9.
322. Boffa MJ, Chalmers RJ. Allopurinol-induced toxic pustuloderma. Br J Dermatol. 1994;131:447.
323. Correia O, Chosidow O, Saiag P, et al. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology. 1993;186:32-7.
324. Goldfarb E, Smyth CJ. Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum. 1966;9:414-23.
325. Guillaume JC, Roujeau JC, Revuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol. 1987;123:1166-70.
326. Hanken I, Schimmer M, Sander CA. Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis. J Dtsch Dermatol Ges. 2010;8:341-6.
327. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9:1617-22.
328. Lee HJ, Kim HS, Park YM, et al. Fixed drug eruption due to allopurinol: positive oral provocation. Ann Dermatol. 2011;23:S402-3.
329. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99-107.
330. Lun K, Harley W. Allopurinol-induced pustular eruption: an unusually mild case. Australas J Dermatol. 2002;43:140-3.
331. Nasser M, Bitterman-Deutsch O, Nassar F. Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. Am J Med Sci. 2005;329:95-8.
332. Ooi CG, Walker P, Sidhu SK, et al. Allopurinol induced generalized eosinophilic pustular folliculitis. Australas J Dermatol. 2006;47:270-3.
333. Stratigos JD, Bartsokas SK, Capetanakis J. Further experiences of toxic epidermal necrolysis incriminating allopurinol, pyrazolone and derivatives. Br J Dermatol. 1972;86:564-7.
334. Thomas J. Dermatologic complications of allopurinol treatment of gout. Rein et Foie. 1969;12:129-33.
335. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol. 2003;139:39-43.
336. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3.
337. Yip LW, Thong BY, Tan AW, et al. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye (Lond). 2005;19:846-53.
338. Becker D, Enk A, Brauninger W, et al. Granuloma anulare disseminatum as a rare side effect of allopurinol. Hautarzt. 1995;46:343-5.
339. Hara Y, Yoshioka M, Yoshiki R, et al. Increased human herpes virus 6 DNA detected by real-time PCR in the saliva of two patients with drug-induced hypersensitivity syndrome. Eur J Dermatol. 2012;22:418-9.
340. Pasero G, Riccioni N, Rizzo G. Prime esperienze con un inibitore della xantina-ossidasi (4-idrossi-pirazolo-(3,4-d)-pirimidina; allopurino) nel trattamento di soggetti gottosi con grave compromissione della funzione renale. La Settimana medica. 1966;54:63-8.
341. Cusido GVI, Aguilar JL. Exantema fijo medicamentoso inducido por alopurinol. Actas Dermo-Sifiliograficas. 1994;85:755-7.
342. Wolf R, Orion E, Marcos B, et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005;23:171-81.
343. Peterson GM, Boyle RR, Francis HW, et al. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol. 1990;39:419-21.
344. Stuart RA, Gow PJ, Bellamy N, et al. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis. N Z Med J. 1991;104:115-7.
345. McClintock AD, Egan AJ, Woods DJ, et al. A survey of allopurinol dosage prescribing. N Z Med J. 1995;108:346-7.
346. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925-34.
347. Smith P, Karlson N, Nair BR. Quality use of allopurinol in the elderly. J Qual Clin Pract. 2000;20:42-3.
348. Stamp L, Gow P, Sharples K, et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med. 2000;30:567-72.
349. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646-50.
350. Athisakul S, Wangkaew S, Louthrenoo W. Inappropriate prescription of allopurinol in a teaching hospital. J Med Assoc Thai. 2007;90:889-94.
351. Atzori L, Pinna AL, Mantovani L, et al. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department - Cagliari University (Italy). J Eur Acad Dermatol Venereol. 2012;26:1424-30.
352. Jung JW, Kim MH, Song WJ, et al. HLA-B58 does not increase allopurinol hypersensitivity among patients with hematologic malignancy. XXII World Allergy Congress; 2012 (4-8 December 2011); Cancun, Mexico: World Allergy Organization; 2012. p. S98.
353. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57:545-9.
354. Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:892-7.
355. Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412-21.
356. Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966;15:863-80.
357. Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978;23:598-605.
358. Rodnan GP, Robin JA, Tolchin SF, et al. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA. 1975;231:1143-7.
359. Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26:445-9.
360. Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol. 2008;14:6-11.
361. Stamp LK, Barclay ML, O'Donnell JL, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther. 2011;90:392-8.
362. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937-43.
363. Bellamy N, Brooks PM, Emmerson BT, et al. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust. 1989;151:531-2 535-7.
364. Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005;44:1038-42.
365. Hall AP, Barry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med. 1967;42:27-37.
366. Rosenfeld JB. Effect of allopurinol administration on serum GFR in normotensive and hypertensive hyperuricemia subjects. Adv Exp Med Biol. 1974;41B:581-96.
367. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74-82.
368. Yu TF, Berger L, Dorph DJ, et al. Renal function in gout. V. Factors influencing the renal hemodynamics. Am J Med. 1979;67:766-71.
369. McGill NW. Gout and other crystal arthropathies. Med J Aust. 1997;166:33-8.
370. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009;2:556-62.
371. Pater C. Hyperuricemia and hypertension: a causal relationship ignored for all too long. Curr Hypertens Rev. 2011;7:41-53.
372. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-90.
373. Johnson RJ, Feig DI, Herrera-Acosta J, et al. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005;45:18-20.
374. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol. 2005;16:1909-19.
375. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36:1072-8.
376. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75(Suppl 5):S13-6.
377. Gaffo AL, Saag KG. Drug treatment of hyperuricemia to prevent cardiovascular outcomes: are we there yet? Am J Cardiovasc Drugs. 2012;12:1-6.
378. See LC, Kuo CF, Chuang FH, et al. Hyperuricemia and metabolic syndrome: associations with chronic kidney disease. Clin Rheumatol. 2011;30:323-30.
379. Goncalves JP, Oliveira A, Severo M, et al. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine. 2012;41:450-7.
380. Lohsoonthorn V, Dhanamun B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res. 2006;37:883-9.
381. Avram Z, Krishnan E. Hyperuricaemia: where nephrology meets rheumatology. Rheumatology. 2008;47:960-4.
382. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-9.
383. Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33:104-9.
384. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179-92.
385. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35:498-501.
386. Kitts A, Feolo M, Helmberg W. Allele and haplotype frequencies. dbMHC anthropology search results (HLA-B*58:01:01). National Center for Biotechnology Information (NCBI). http://www.ncbi.nlm.nih.gov/projects/gv/mhc/ ihwg.cgi. Accessed 14 Dec 2012.
387. Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica. 1989;179:32-3.
388. Cristallo AF, Schroeder J, Citterio A, et al. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011;38:303-9.
389. Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21:303-7.
390. Phillips EJ, Chung WH, Mockenhaupt M, et al. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011;127:S60-6.
391. Somkrua R, Eickman EE, Saokaew S, et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.
392. Somkrua R, Chaiyakunapruk N, Tassaneeyakul W. What cost of HLA-B*5801 genotyping would be cost-effective for the prevention of allopurinol-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in Thailand: analyses using a decision-analytic model. Value Health. 2010;13:A564-5.
393. Yeo SI. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region. Int J Rheum Dis. 2013.
394. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-6.
395. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-7.
396. Singh JA, Hodges JS, Toscano JP, et al. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57:822-9.
397. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26-35.
398. Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69:1305-9.
399. Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol. 2004;10:308-14.
400. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-63.
401. Fuldeore MJ, Riedel AA, Zarotsky V, et al. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011;12:36.
402. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(679-87):e1.
403. Sharpe CR. A case-control study of alcohol consumption and drinking behaviour in patients with acute gout. Can Med Assoc J. 1984;131:563-7.
404. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004-7.
405. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-51.
406. Tikly M, Bellingan A, Lincoln D, et al. Risk factors for gout: a hospital-based study in urban black South Africans. Rev Rhum Engl Ed. 1998;65:225-31.
407. McGill NW. Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol. 2000;14:445-60.
408. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29:1350-5.
409. Mandell BF. Hyperuricemia and gout: a reign of complacency. Cleve Clin J Med. 2002;69:589-90 92-3.
410. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67:960-6.
411. Shiohara T, Iijima M, Ikezawa Z, et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156:1083-4.
412. Pritchett JC, Nanau RM, Neuman MG. The link between hypersensitivity syndrome reaction development and human herpes virus-6 reactivation. Int J Hepatol. 2012;2012:723062.
413. Shiohara T, Kano Y, Takahashi R, et al. Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management. Chem Immunol Allergy. 2012;97:122-38.
414. Criado PR, Criado RF, Avancini Jde M, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012;87:435-49.
415. Hirahara K, Kano Y, Mitsuyama Y, et al. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions. Clin Exp Dermatol. 2010;35:863-8.
416. Mockenhaupt M. Allopurinol is the most frequent cause of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Dermatol. 2012;7:213-5.
417. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-7.
418. de Klerk E, van der Heijde D, Landewe R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30:44-54.
419. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31:1575-81.
420. Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609-13.
421. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38:396-402.
422. Bull PW, Scott JT. Intermittent control of hyperuricaemia in the treatment of gout. Adv Exp Med Biol. 1989;253A:251-5.
423. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11:S435-42 quiz S65-8.
424. Harrold LR, Mazor KM, Velten S, et al. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010;6:263-71.
425. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490-5.
426. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59:809-20.
427. Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62:1439-44.
428. Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol. 2007;7:299-303.
429. Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol. 2010;10:291-6.
430. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005;152:968-74.
431. Andrade P, Brinca A, Goncalo M. Patch testing in fixed drug eruptions: a 20-year review. Contact Dermat. 2011;65:195-201.
432. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209-16.
433. Waton J, Trechot P, Loss-Ayav C, et al. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions. Br J Dermatol. 2009;160:786-94.
434. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy. 2007;37:989-99.
435. Bircher AJ, Scherer K. Delayed cutaneous manifestations of drug hypersensitivity. Med Clin N Am. 2010;94:711-25 x.
436. Kim SC, Newcomb C, Margolis D, et al. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken). 2012.
437. Ryu HJ, Song R, Kim HW, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol. 2012.
438. Riedel MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781-91.
439. Rieder MJ. Immune mediation of hypersensitivity adverse drug reactions: implications for therapy. Expert Opin Drug Saf. 2009;8:331-43.
440. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.
441. Worswick S, Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther. 2011;24:207-18.
442. Michaels B. The role of systemic corticosteroid therapy in erythema multiforme major and Stevens-Johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol. 2009;2:51-5.
443. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33-6.
444. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81-8.
445. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246-55.
446. Pasic S. Intravenous immunoglobulin in toxic epidermal necrolysis. Int J Dermatol. 2006;45:1117-8.
447. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics. 2003;112:1430-6.
448. Al-Mutairi N, Arun J, Osama NE, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol. 2004;43:847-51.
449. Tan AW, Thong BY, Yip LW, et al. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol. 2005;32:1-6.
450. Mangla K, Rastogi S, Goyal P, et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71:398-400.
451. Stella M, Clemente A, Bollero D, et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33:452-9.
452. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33-40.
453. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006;6:543-9.
454. Trent J, Halem M, French LE, et al. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg. 2006;25:91-3.
455. Momin SB. Review of intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Clin Aesthet Dermatol. 2009;2:51-8.
456. 2 laser resurfacing. Laryngoscope. 2002;112:1239-42.
457. Aronson JK. Anecdotes as evidence. BMJ. 2003;326:1346.
458. Kelly WN. The quality of published adverse drug event reports. Ann Pharmacother. 2003;37:1774-8.
459. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385-96.
460. Loke YK, Price D, Derry S, et al. Case reports of suspected adverse drug reactions - systematic literature survey of follow-up. BMJ. 2006;332:335-9.
461. Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database. Drug Saf. 2010;33:765-73.
462. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf. 2007;16:581-7.
463. Longmore JM, Wilkinson IB, Rajagopalan SR. Oxford handbook of clinical medicine. 6th ed. New York: Oxford University Press; 2004.